These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6608470)

  • 41. Low circulating T-helper cells in relapsing multiple myeloma.
    Hicks MJ; Durie BG; Slymen DJ
    J Clin Lab Anal; 1989; 3(4):202-8. PubMed ID: 2527296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The periodic acid-Schiff reaction and prognosis in children with acute lymphoblastic leukemia.
    Raney RB; Festa RS; Waldman MT; Manson D; Hann HW
    Am J Hematol; 1979; 6(1):27-34. PubMed ID: 313153
    [No Abstract]   [Full Text] [Related]  

  • 43. [Indicators of nonspecific immunity in plasmacytoma].
    Urasiński I; Sochacka-Kuzko B; Fiedorowicz-Fabrycy I; Wichert K
    Pol Arch Med Wewn; 1980 Dec; 64(6):511-7. PubMed ID: 6970925
    [No Abstract]   [Full Text] [Related]  

  • 44. Idiotypic studies on myeloma B cells.
    Van Acker A; Conte F; Hulin N; Urbain J
    Eur J Cancer (1965); 1979 May; 15(5):627-35. PubMed ID: 116854
    [No Abstract]   [Full Text] [Related]  

  • 45. [Kinetic and immunological studies in human myeloma: clinical implications (author's transl)].
    Pileri A; Boccadoro M
    Haematologica; 1979 Oct; 64 Suppl():30-4. PubMed ID: 120281
    [No Abstract]   [Full Text] [Related]  

  • 46. Peripheral blood monoclonal B-cells predict the event free survival in multiple myeloma.
    Mitterer M; Lanthaler AJ; Schnabel B; Svaldi M; Oduncu F; Coser P; Emmerich B; Huemer H; Straka C
    Leuk Lymphoma; 2001 Apr; 41(3-4):387-95. PubMed ID: 11378552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of monoclonal B lymphocytes in multiple myeloma by immunofluorescence tests of surface immunoglobulins.
    Sato I; Abo T; Onodera S; Kumagai K
    Scand J Haematol; 1978 Nov; 21(5):433-44. PubMed ID: 366730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation.
    Kiel K; Cremer FW; Rottenburger C; Kallmeyer C; Ehrbrecht E; Atzberger A; Hegenbart U; Goldschmidt H; Moos M
    Bone Marrow Transplant; 1999 May; 23(10):1019-27. PubMed ID: 10373068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma.
    Perri RT; Oken MM; Kay NE
    J Lab Clin Med; 1982 Apr; 99(4):512-9. PubMed ID: 6460827
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparative evaluation of the effectiveness of mono- and polychemotherapy programs in patients with multiple myeloma].
    Abdulkadyrov KM; Bessmel'tsev SS
    Klin Med (Mosk); 1992; 70(9-10):57-60. PubMed ID: 1474818
    [No Abstract]   [Full Text] [Related]  

  • 51. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
    Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
    G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
    [No Abstract]   [Full Text] [Related]  

  • 52. [Monochemotherapy and polychemotherapy of multiple myeloma].
    Kraj M; Maj S; Rostkowska J; Pogłód R; Słomkowski M
    Nowotwory; 1984; 34(1):65-75. PubMed ID: 6377239
    [No Abstract]   [Full Text] [Related]  

  • 53. Multiple myeloma: an immunologic profile. I. Peripheral blood studies.
    MacKenzie MR; Paglieroni T
    J Immunol; 1977 May; 118(5):1864-71. PubMed ID: 140196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications.
    Mellstedt H; Holm G; Björkholm M
    Adv Cancer Res; 1984; 41():257-89. PubMed ID: 6428176
    [No Abstract]   [Full Text] [Related]  

  • 55. Expansion of Th
    Harada T; Miki H; Cui Q; Oda A; Amachi R; Teramachi J; Bat-Erdene A; Sogabe K; Iwasa M; Fujii S; Nakamura S; Kagawa K; Yoshida S; Endo I; Aihara K; Ozaki S; Matsumoto T; Abe M
    Leukemia; 2017 Jan; 31(1):258-262. PubMed ID: 27698446
    [No Abstract]   [Full Text] [Related]  

  • 56. Monitoring myeloma: light chain isotype suppression. A new parameter.
    Wearne A; Joshua DE; Kronenberg H
    Aust N Z J Med; 1985 Oct; 15(5):629-33. PubMed ID: 3937514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Changes of electrocoagulographic parameters and erythrocyte deformability in multiple myeloma patients on various regimens of polychemotherapy].
    Bessmel'tsev SS; Katsadze IuL
    Klin Med (Mosk); 1991 Nov; 69(11):69-73. PubMed ID: 1808414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Indications for chemotherapy in multiple myeloma].
    Heyll A; Aul C
    Dtsch Med Wochenschr; 1996 May; 121(20):675. PubMed ID: 8635404
    [No Abstract]   [Full Text] [Related]  

  • 59. [The effect of chemotherapy on the killer activity of the peripheral blood leukocytes in patients with multiple myeloma].
    Vozniuk VP
    Lik Sprava; 1998; (2):88-91. PubMed ID: 9670667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple myeloma.
    Oken MM
    Med Clin North Am; 1984 May; 68(3):757-87. PubMed ID: 6379340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.